Healthtech CMR Surgical closes £301.9m with Stryker
This article covers CMR Surgical, a surgical robotics startup, which has closed a growth funding round after Stryker agreed a preferred equity investment of approximately £301.9m and an exclusive option to acquire the startup in the future. The investment supports expansion of CMR’s Versius surgical robotics platform, granting Stryker exclusive United States sales rights and targeting adoption in hospitals and ambulatory surgical centres.
CMR Surgical has closed a growth funding round after Stryker agreed a preferred equity investment of approximately £301.9m and an exclusive option to acquire the company in the future. The deal pairs CMR’s Versius surgical robotics platform with Stryker’s commercial scale and gives Stryker exclusive U.S. sales rights for the portfolio — a move that could speed the robot’s roll‑out in the world’s largest hospital market and reshape competition in surgical robotics.
Why it matters
The agreement comes as demand for robotic‑assisted surgery grows and hospitals look for solutions that fit existing operating room workflows. By combining CMR’s modular Versius platform and clinical experience with Stryker’s sales reach and relationships in hospitals and ambulatory surgical centres, the partnership aims to accelerate adoption of soft‑tissue robotic systems outside incumbent players.
For the UK healthtech ecosystem, the transaction signals that large US medtech firms remain prepared to back British robotics companies with sizeable capital injections paired with commercial partnerships rather than immediate buyouts. The structure — preferred equity plus an exclusive acquisition option — gives CMR capital to expand while creating a clear path to full integration should Stryker exercise the option.
Inside the product
Versius is a second‑generation soft‑tissue surgical robot built around a modular architecture intended to work within standard operating room setups. CMR describes the platform as supporting a broad range of soft tissue procedures and offering flexibility for surgeon access and different sites of care, including hospitals and ambulatory surgical centres. The company is also developing Versius Plus, its next‑generation system, which it says is targeted at scaling robotic minimal access surgery in real‑world clinical environments.
CMR was founded in 2014 and is headquartered in Cambridge. The company has built clinical experience globally for the Versius platform and positions its technology as an alternative designed to integrate with existing workflows rather than requiring radical changes to theatre practice.
Who are the investors?
The investor and commercial partner in this transaction is Stryker (NYSE:SYK). Stryker will make an approximately £301.9m preferred equity investment in CMR Surgical. The investment grants Stryker an exclusive option to acquire 100% of CMR Surgical’s outstanding equity in the future, subject to the agreement’s terms, regulatory approvals and customary closing conditions.
Under the commercial terms, Stryker will act as the exclusive U.S. sales agent for the Versius portfolio. CMR Surgical will retain responsibility for portfolio development and commercialization outside the United States. The companies say the financing is intended to support continued innovation and global commercial expansion of Versius.
In the announcement, Andy Pierce, Group President, Medsurg and Neurotechnology, Stryker, said:
Soft-tissue robotics is a high-growth adjacency and a natural extension of Stryker’s strengths in endoscopy, visualization and enabling technologies. We have evaluated the segment carefully for years, and this alliance represents a thoughtful and disciplined entry that combines the complementary strengths of both companies.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
In the announcement, Massimiliano Colella, Chief Executive Officer of CMR Surgical, said:
This strategic alliance is a significant milestone for CMR and a strong endorsement of the technology, clinical experience and global business we have built. Stryker’s investment will give us additional strength to accelerate innovation and the continued global expansion of the Versius portfolio, while its scale and deep customer relationships create a significant growth opportunity in the United States. We also look forward to welcoming Andy Pierce to our board of directors and benefiting from his more than 30 years of MedTech leadership experience at Stryker as we continue expanding access to robotic-assisted surgery globally. Colella’s comments underline that CMR expects to keep product and non‑US commercial control while leveraging Stryker’s US infrastructure to increase penetration in a key market.
The bigger picture
The deal highlights two trends in European healthtech financing. First, strategic partnerships with large medtech firms are increasingly used to de‑risk international expansion for startups while preserving some operational independence. Second, the US market continues to be a decisive battleground for surgical robotics; securing a strong US commercial partner can materially accelerate adoption and scale.
The transaction is subject to regulatory approvals and customary closing conditions. If completed, it may encourage further investment and consolidation activity in surgical robotics and the broader healthtech sector as UK and European startups look for routes to global commercial scale.
Click here for a full list of 7,589+ startup investors in the UK